Fc glycans of therapeutic antibodies as critical quality attributes

Glycobiology

Volumn 25, Issue 12, 2015, Pages 1325-1334

  Reusch, Dietmar ^a   Tejada, Max L ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b GENENTECH INC   (United States)

Author keywords

Biologic activity; Critical quality attribute; Fc glycans; Immunogenicity; Therapeutic antibody

Indexed keywords

FC GLYCAN DERIVATIVE; GLYCAN DERIVATIVE; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; POLYSACCHARIDE;

CRITICAL QUALITY ATTRIBUTE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MANUFACTURE; DRUG QUALITY; DRUG SAFETY; DRUG STRUCTURE; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PATIENT SAFETY; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; ADVERSE EFFECTS; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; IMMUNIZATION; IMMUNOLOGY; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNIZATION; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES;

EID: 84955194105     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwv065     Document Type: Review

References (118)

1. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. 2007. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol. 179:4580-4588.
2. Alessandri L, Ouellette D, Acquah A, Rieser M, Leblond D, Saltarelli M, Radziejewski C, Fujimori T, Correia I. 2012. Increased serum clearance of oligomannose species present on a human IgG1 molecule. MAbs. 4:509-520.
3. Allavena P, Chieppa M, Monti P, Piemonti L. 2004. From pattern recognition receptor to regulator of homeostasis: The double-faced macrophage mannose receptor. Crit Rev Immunol. 24:179-192.
4. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. 2008. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 320:373-376.
5. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. 2008b. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA. 105:19571-19578.
6. Baldo BA. 2013. Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology. 2:e26333.
7. Bardor M, Nguyen DH, Diaz S, Varki A. 2005. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem. 280:4228-4237.
8. Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, Goetsch L, Wurch T, Van Dorsselaer A, Corvaia N. 2008. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol. 9:482-501.
9. Bibeau F, Lopez-Crapez E, Di FF, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frebourg T, Michel P, et al. 2009. Impact of Fc{gamma} RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 27:1122-1129.
10. Borrebaeck CK, Malmborg AC, Ohlin M. 1993. Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? Immunol Today. 14:477-479.
11. Bosques CJ, Collins BE, Meador JW III, Sarvaiya H, Murphy JL, Dellorusso G, Bulik DA, Hsu IH, Washburn N, Sipsey SF, et al. 2010. Chinese hamster ovary cells can produce galactose-alpha-1,3-galactose antigens on proteins. Nat Biotechnol. 28:1153-1156.
12. Bowden TA, Baruah K, Coles CH, Harvey DJ, Yu X, Song BD, Stuart DI, Ariescu AR, Scanlan CN, Jones EY, et al. 2012. Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. J Am Chem Soc. 134:17554-17563.
13. Boyd PN, Lines AC, Patel AK. 1995. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol. 32:1311-1318.
14. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 99:754-758.
15. Chen X, Liu YD, Flynn GC. 2009. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology. 19:240-249.
16. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, et al. 2008. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 358:1109-1117.
17. Chung S, Quarmby V, Gao X, Ying Y, Lin L, Reed C, Fong C, Lau W, Qiu ZJ, Shen A, et al. 2012. Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcgamma receptor binding and antibody-dependent cell-mediated cytotoxicity activities. MAbs. 4:326-340.
18. Daeron M. 1997. Fc receptor biology. Annu Rev Immunol. 15:203-234.
19. Deglon N, Aubert V, Spertini F, Winkel L, Aebischer P. 2003. Presence of Gal-alpha1,3Gal epitope on xenogeneic lines: Implications for cellular gene therapy based on the encapsulation technology. Xenotransplantation. 10:204-213.
20. Deng R, Jin F, Prabhu S, Iyer S. 2012. Monoclonal antibodies: What are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol. 8:141-160.
21. Dong X, Storkus WJ, Salter RD. 1999. Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. J Immunol. 163:5427-5434.
22. Durocher Y, Butler M. 2009. Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol. 20:700-707.
23. Ferrara C, Brünker P, Suter T, Moser S, Puntener U, Umana P. 2006. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1,4-N-acetylglucosaminyltransferase III and Golgi alphamannosidase II. Biotechnol Bioeng. 93:851-861.
24. Fukushima K, Takasaki S. 1993. Suppressive role of sialylated N-glycans in Fc receptor-mediated phagocytosis by macrophages. Biochem Biophys Res Commun. 192:333-337.
25. Galili U. 2001. The alpha-Gal epitope (Galalpha1-3Galbeta1-4GlcNAc-R) in xenotransplantation. Biochimie. 83:557-563.
26. Galili U, Rachmilewitz EA, Peleg A, Flechner I. 1984. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med. 160:1519-1531.
27. Gerber JS, Mosser DM. 2001. Stimulatory and inhibitory signals originating from the macrophage Fcgamma receptors. Microbes Infect. 3:131-139.
28. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A. 2010. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol. 28:863-867.
29. Ghetie V, Ward ES. 2000. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol. 18:739-766.
30. Ghirlando R, Lund J, Goodall M, Jefferis R. 1999. Glycosylation of human IgG-Fc: Influences on structure revealed by differential scanning microcalorimetry. Immunol Lett. 68:47-52.
31. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. 2011. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 21:949-959.
32. Golay J, Da RF, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M. 2013. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 122:3482-3491.
33. Ha S, Ou Y, Vlasak J, Li Y, Wang S, Vo K, Du Y, Mach A, Fang Y, Zhang N. 2011. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. Glycobiology. 21:1087-1096.
34. Harris RJ. 2005. Heterogeneity of recombinant antibodies: Linking structure to function. Dev Biol (Basel). 122:117-127.
35. Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M. 2014. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol. 192:1252-2260.
36. Higgins E. 2010. Carbohydrate analysis throughout the development of a protein therapeutic. Glycoconj J. 27:211-225.
37. Hodoniczky J, Zheng YZ, James DC. 2005. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog. 21:1644-1652.
38. Hokke CH, Bergwerff AA, van Dedem GW, van OJ, Kamerling JP, Vliegenthart JF. 1990. Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Lett. 275:9-14.
39. Holland M, Yagi H, Takahashi N, Kato K, Savage CO, Goodall DM, Jefferis R. 2006. Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochim Biophys Acta. 1760:669-677.
40. Houde D, Peng Y, Berkowitz SA, Engen JR. 2010. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics. 9:1716-1728.
41. Hristodorov D, Fischer R, Joerissen H, Muller-Tiemann B, Apeler H, Linden L. 2013. Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies. Mol Biotechnol. 53:326-335.
42. Huang L, Biolsi S, Bales KR, Kuchibhotla U. 2006. Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization. Anal Biochem. 349:197-207.
43. Jefferis R. 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog. 21:11-16.
44. Jefferis R. 2006. A sugar switch for anti-inflammatory antibodies. Nat Biotechnol. 24:1230-1231.
45. Jefferis R. 2009a. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 8:226-234.
46. Jefferis R. 2009b. Recombinant antibody therapeutics: The impact of glycosylation on mechanisms of action. Trends Pharmacol Sci. 30:356-362.
47. Jefferis R. 2012. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys. 526:159-166.
48. Jenkins N, Parekh RB, James DC. 1996. Getting the glycosylation right: Implications for the biotechnology industry. Nat Biotechnol. 14:975-981.
49. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. 2011. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov. 10:101-111.
50. Jones AJ, Papac DI, Chin EH, Keck R, Baughman SA, Lin YS, Kneer J, Battersby JE. 2007. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology. 17:529-540.
51. Jung ST, Kang TH, Kelton W, Georgiou G. 2011. Bypassing glycosylation: Engineering aglycosylated full-length IgG antibodies for human therapy. Curr Opin Biotechnol. 22:858-867.
52. Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, Tucker PW, Georgiou G. 2010. Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells. Proc Natl Acad Sci USA. 107:604-609.
53. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, et al. 2010. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 70:4481-4489.
54. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, et al. 2007. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, complex types. Glycobiology. 17:104-118.
55. Kaneko Y, Nimmerjahn F, Ravetch JV. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 313:670-673.
56. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, McDonald Ju, Orr SJ, Berger M, Petzold D, et al. 2012. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med. 18:1401-1406.
57. Keck R, Nayak N, Lerner L, Raju S, Ma S, Schreitmueller T, Chamow S, Moorhouse K, Kotts C, Jones A. 2008. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals. 36:49-60.
58. Kuo TT, de Muinck EJ, Claypool SM, Yoshida M, Nagaishi T, Aveson VG, Lencer WI, Blumberg RS. 2009. N-Glycan moieties in neonatal Fc receptor determine steady-state membrane distribution and directional transport of IgG. J Biol Chem. 284:8292-8300.
59. Lammerts van Bueren JJ, Rispens T, Verploegen S, van der Palen-Merkus T, Stapel S, Workman LJ, James H, van Berkel PH, van de Winkel JG, Platts-Mills TA, et al. 2011. Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol. 29:574-576.
60. Larsen RD, Rajan VP, Ruff MM, Kukowska-Latallo J, Cummings RD, Lowe JB. 1989. Isolation of a cDNA encoding a murine UDPgalactose:beta-D-galactosyl-1,4-N-acetyl-D-glucosaminide alpha-1,3-galactosyltransferase: Expression cloning by gene transfer. Proc Natl Acad Sci USA. 86:8227-8231.
61. Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S. 2013. Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs. 5:896-903.
62. Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J, Risteli L, Lee YC, Feizi T, Langen H, Nussenzweig MC. 2002. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science. 295:1898-1901.
63. Lim A, Reed-Bogan A, Harmon BJ. 2008. Glycosylation profiling of a therapeutic recombinant monoclonal antibody with two N-linked glycosylation sites using liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer. Anal Biochem. 375:163-172.
64. Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R. 1996. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol. 157:4963-4969.
65. Lund J, Takahashi N, Pound JD, Goodall M, Nakagawa H, Jefferis R. 1995. Oligosaccharide-protein interactions in IgG can modulate recognition by Fc gamma receptors. FASEB J. 9:115-119.
66. Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y, Kubota A, Shitara K, Nakamura K. 2007. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol. 44:3122-3131.
67. Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, Otaki S, Satoh M, Shitara K, Kato K. 2007. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol. 368:767-779.
68. Milland J, Sandrin MS. 2006. ABO blood group and related antigens, natural antibodies and transplantation. Tissue Antigens. 68:459-466.
69. Millward TA, Heitzmann M, Bill K, Langle U, Schumacher P, Forrer K. 2008. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals. 36:41-47.
70. Mimura Y, Ashton PR, Takahashi N, Harvey DJ, Jefferis R. 2007. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. J Immunol Methods. 326:116-126.
71. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. 2000. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms. Mol Immunol. 37:697-706.
72. Mori K, Kuni-Kamochi R, Yamane-Ohnuki N, Wakitani M, Yamano K, Imai H, Kanda Y, Niwa R, Iida S, Uchida K, et al. 2004. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng. 88:901-908.
73. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, et al. 2008. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 26:1789-1796.
74. Newkirk MM, Novick J, Stevenson MM, Fournier MJ, Apostolakos P. 1996. Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice. Clin Exp Immunol. 106:259-264.
75. Nimmerjahn F, Anthony RM, Ravetch JV. 2007. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci USA. 104:8433-8437.
76. Nimmerjahn F, Ravetch JV. 2008. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 26:513-533.
77. Nimmerjahn F, Ravetch JV. 2006. Fcgamma receptors: Old friends and new family members. Immunity. 24:19-28.
78. Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K. 2004. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res. 10:6248-6255.
79. Noguchi A, Mukuria CJ, Suzuki E, Naiki M. 1996. Failure of human immunoresponse to N-glycolylneuraminic acid epitope contained in recombinant human erythropoietin. Nephron. 72:599-603.
80. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K. 2004. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol. 336:1239-1249.
81. Pacis E, Yu M, Autsen J, Bayer R, Li F. 2011. Effects of cell culture conditions on antibody N-linked glycosylation - what affects high mannose 5 glycoform. Biotechnol Bioeng. 108:2348-2358.
82. Padler-Karavani V, Yu H, Cao H, Chokhawala H, Karp F, Varki N, Chen X, Varki A. 2008. Diversity in specificity, abundance, composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease. Glycobiology. 18:818-830.
83. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K. 1985. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 316:452-457.
84. Paulus KE, Mahler V, Pabst M, Kogel KH, Altmann F, Sonnewald U. 2011. Silencing beta1,2-xylosyltransferase in transgenic tomato fruits reveals xylose as constitutive component of Ige-binding epitopes. Front Plant Sci. 2:42.
85. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG, et al. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood. 112:2390-2399.
86. Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. 2007. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem. 364:8-18.
87. Radaev S, Sun P. 2002. Recognition of immunoglobulins by Fcgamma receptors. Mol Immunol. 38:1073-1083.
88. Ravetch JV. 1997. Fc receptors. Curr Opin Immunol. 9:121-125.
89. Ravetch JV, Bolland S. 2001. IgG Fc receptors. Annu Rev Immunol. 19:275-290.
90. Reusch D, Haberger M, Maier B, Maier M, Kloseck R, Zimmermann B, Hook M, Szabo Z, Tep S, Wegstein J, et al. 2015. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles - part 1: Separation-based methods. MAbs. 7:167-179.
91. Ritamo I, Cloutier M, Valmu L, Neron S, Rabina J. 2013. Comparison of the glycosylation of in vitro generated polyclonal human IgG and therapeutic immunoglobulins. Mol Immunol. 57:255-262.
92. Roopenian DC, Akilesh S. 2007. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol. 7:715-725.
93. Rothman RJ, Perussia B, Herlyn D, Warren L. 1989. Antibody-dependent cytotoxicity mediated by natural killer cells is enhanced by castanospermine-induced alterations of IgG glycosylation. Mol Immunol. 26:1113-1123.
94. Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV, Wittrup KD. 2008. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. Proc Natl Acad Sci USA. 105:20167-20172.
95. Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol. 44:1524-1534.
96. Shatz W, Chung S, Li B, Marshall B, Tejada M, Phung W, Sandoval W, Kelley RF, Scheer JM. 2013. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs. 5:872-881.
97. Sheeley DM, Merrill BM, Taylor LC. 1997. Characterization of monoclonal antibody glycosylation: Comparison of expression systems and identification of terminal alpha-linked galactose. Anal Biochem. 247:102-110.
98. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 277:26733-26740.
99. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 278:3466-3473.
100. Sondermann P, Kaiser J, Jacob U. 2001. Molecular basis for immune complex recognition: A comparison of Fc-receptor structures. J Mol Biol. 309:737-749.
101. Strasser R, Altmann F, Mach L, Glossl J, Steinkellner H. 2004. Generation of Arabidopsis thaliana plants with complex N-glycans lacking beta1,2-linked xylose and core alpha1,3-linked fucose. FEBS Lett. 561:132-136.
102. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, Muchmore E. 2003. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA. 100:12045-12050.
103. Tao MH, Morrison SL. 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol. 143:2595-2601.
104. Tejada ML, Thomann M, Reusch D. 2015. Fc-galactosylation modulates antibody dependent cellular cytotoxicity of therapeutic antibodies. Mol Immunol. Submitted.
105. Tekoah Y, Ko K, Koprowski H, Harvey DJ, Wormald MR, Dwek RA, Rudd PM. 2004. Controlled glycosylation of therapeutic antibodies in plants. Arch Biochem Biophys. 426:266-278.
106. Tesar DB, Bjorkman PJ. 2010. An intracellular traffic jam: Fc receptor-mediated transport of immunoglobulin G. Curr Opin Struct Biol. 20:226-233.
107. Thomann M, Schlothauer T, Dashivets T, Malik S, Avenal C, Bulau P, Rueger P, Reusch D. 2015. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and adcc activity. PLoS ONE. 10:e0134949.
108. Tsuchiya N, Endo T, Matsuta K, Yoshinoya S, Aikawa T, Kosuge E, Takeuchi F, Miyamoto T, Kobata A. 1989. Effects of galactose depletion from oligosaccharide chains on immunological activities of human IgG. J Rheumatol. 16:285-290.
109. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. 1999. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 17:176-180.
110. Varki A. 2007. Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins. Nature. 446:1023-1029.
111. Wawrzynczak EJ, Cumber AJ, Parnell GD, Jones PT, Winter G. 1992. Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains. Mol Immunol. 29:213-220.
112. Wawrzynczak EJ, Parnell GD, Cumber AJ, Jones PT, Winter G. 1989. Blood clearance in the mouse of an aglycosyl recombinant monoclonal antibody. Biochem Soc Trans. 17:1061-1062.
113. Weis WI, Taylor ME, Drickamer K. 1998. The C-type lectin superfamily in the immune system. Immunol Rev. 163:19-34.
114. Wileman TE, Lennartz MR, Stahl PD. 1986. Identification of the macrophage mannose receptor as a 175-kDa membrane protein. Proc Natl Acad Sci USA. 83:2501-2505.
115. 2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med. 180:1087-1096.
116. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, et al. 2004. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 87:614-622.
117. Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R. 2012. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs. 4:475-487.
118. Zhu A, Hurst R. 2002. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation. 9:376-381.